evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,497 questions · 1,590 findings · 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 281 · 17.7%GRADE not reported 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Minor non‐GI bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis probably leads to higher minor non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).

1 finding from 1 review

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Recurrent VTE · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in recurrent VTE compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Laparoscopy vs laparotomy

Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.

Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).

1 finding from 1 review

Laparoscopy vs laparotomy

Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.

Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).

1 finding from 1 review